

---

## **CHROMEDX SUBMITS US PROVISIONAL PATENT APPLICATION FOR RECENTLY DEVELOPED ASPECTS OF HEMOPALM BLOOD ANALYSIS SYSTEM**

March 10, 2015 – ChroMedX Corp. (the “**Company**”) (CSE: CHX, OTC: MNLIF, Frankfurt: EIY2), a developer of in vitro diagnostics and point-of-care testing (POCT) technologies is pleased to announce the filing of a second US Provisional Patent Application pertaining to the HemoPalm Cartridge and Analyzer system.

The second US Provisional Patent Application **No. 62/114,700** entitled “Joint Spectroscopic and Biosensor System for Point-of-Care Testing” was filed on 11<sup>th</sup> Feb 2015, and describes recently developed aspects of the Company’s HemoPalm Cartridge and Analyzer system. The first US Provisional Patent Application **No. 62/006,066** was filed on 31<sup>st</sup> May 2014. In May 2015, an international patent application (PCT) will be filed, claiming priority to the two US Provisional Patent Applications. This PCT has the potential to effectively extend the lifespan of our issued US Patent pertaining to HemoPalm, and to provide patent protection outside the US, in particular Europe, China and India.

“We continue our efforts in expanding the Company’s Intellectual Property portfolio and are very pleased with the progress made to date”, said Dr. Wayne Maddever , ChroMedX Corp., President & CEO

The Company’s HemoPalm and Ultrafiltration technologies are covered by several issued and pending patents. A list of issued and pending patents can be found on the company's website here: <http://www.chromedx.com/intellectual-property/>

### **About ChroMedX Corp.**

ChroMedX Corp. is a medical technology company focused on the development of novel medical devices for in vitro diagnostics and point-of-care testing. The devices are protected by the Company’s issued and pending patents, pertaining to blood collection, analysis and plasma/serum processing.

### **Follow ChroMedX Corp.:**

Website: [www.ChroMedX.com](http://www.ChroMedX.com)

Facebook: [facebook.com/ChroMedXcorp](https://facebook.com/ChroMedXcorp)

Twitter: [www.twitter.com/ChroMedXcorp](https://www.twitter.com/ChroMedXcorp)

### **Investor Enquiries:**

W. Clark Kent  
Corporate Development  
647-519-2646  
[ckent@ChroMedX.com](mailto:ckent@ChroMedX.com)

---

***NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.***

## **Forward-looking Information Cautionary Statement**

Except for statements of historic fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements are based on the opinions and estimates at the date the statements are made, and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking statements including, but not limited to delays or uncertainties with regulatory approvals, including that of the CSE. There are uncertainties inherent in forward-looking information, including factors beyond the Company's control. The Company undertakes no obligation to update forward-looking information if circumstances or management's estimates or opinions should change except as required by law. The reader is cautioned not to place undue reliance on forward-looking statements. Additional information identifying risks and uncertainties that could affect financial results is contained in the Company's filings with Canadian securities regulators, which filings are available at [www.sedar.com](http://www.sedar.com)